India’s GLP-1 market opened up almost overnight. Semaglutide came off patent in March 2026, and multiple Indian manufacturers launched generics within days. The molecule itself, a 31-amino-acid peptide, is one of the harder things to make well in pharmaceutical manufacturing. Those two facts together define what GLP-1 actually means for Indian pharma: a category in which the right to market the drug and the ability to manufacture it well are not the same thing.

The demand side of the equation is straightforward.  National Family Health Survey 5 (2019-21) recorded a 91 per cent rise in overweight and obesity among Indian women (12.6 per cent to 24.0 per cent) and a 146 per cent rise among men (9.3 per cent to 22.9 per cent) over the previous half-decade.

The global semaglutide market, valued at approximately $28 billion in 2024, is projected to grow to nearly $94 billion by 2035, reflecting a steady CAGR of over 10%. More broadly, GLP-1–based weight-loss therapies are expected to anchor a market that could exceed $100 billion globally by the end of the decade.

Prescribing has broadened beyond endocrinology and diabetology. Cardiologists, gastroenterologists, and gynaecologists are now writing GLP-1 scripts as obesity’s downstream effects pull more specialties into the same drug class. That broadens demand. It also broadens the safety, monitoring, and counselling burden on a system that does not have the post-prescription infrastructure these drugs need.

What patent expiry actually opens up

The recent patent expiry of semaglutide in India has triggered one of the fastest generic entry cycles in recent pharmaceutical history, with several Indian companies launching versions within days. This patent cliff has opened up a sizable revenue opportunity exceeding Rs 50 billion for generic drug manufacturers over the next 12-15 months.

According to CareEdge Ratings, the GLP-1 market, valued at around ₹1,000–1,200 crore in 2025, is expected to grow to ₹4,500–5,000 crore by 2030, with patent expiry acting as a key driver. But this opportunity can’t just be measured by volume and expansion. The patent expiry in emerging markets such as India, China, and Brazil forecasts 5–8% global market share erosion among innovator companies that can increase at a rate of up to 12–18% over the next few years. This share is now genuinely contestable. The Indian companies that capture this window will be the ones that can manufacture the molecule to global quality standards, which is a much smaller subset than the ones that filed for it.

The peptide stack is a different stack

Semaglutide is not a small molecule. It is a 31-amino-acid peptide. Making it at commercial scale to USFDA and EMA standards is a different manufacturing problem from anything India’s generics economy was built to solve. Solid-phase or liquid-phase synthesis, downstream purification, characterisation by high-resolution mass spectrometry, control of related-substance and impurity profiles at parts-per-million levels. Every step compounds the previous one’s tolerance.

For decades, India’s pharmaceutical leadership has been anchored in its ability to deliver affordable generics at scale. However, the manufacturing of GLP-1 drugs demands a fundamentally different approach.

Peptide synthesis requires precision at every stage, from amino acid sequencing to folding and purification. Even minor deviations can compromise product quality, making consistency and control non-negotiable. As a result, companies are investing in advanced synthesis platforms, high-resolution analytical tools, and state-of-the-art manufacturing environments designed to meet global regulatory expectations.

This transition is also driving a renewed focus on backward integration. Securing control over critical raw materials and intermediates is becoming essential not only for cost management but also for ensuring supply chain resilience and maintaining stringent quality standards.

The deployment problem

The gap between the addressable population and the prescribed population is the actual story. As per market analysis, only about 200,000 patients are currently on GLP-1 treatment despite a potential population of hundreds of millions living with obesity or diabetes. Generic competition will compress prices further, but compression alone does not put the drug in the hands of the patient who needs it. Patient identification, GP-level training, the cost of monitoring, and the absence of insurance reimbursement are infrastructure questions, not pricing questions.

On the production front, the capital requirements for peptide manufacturing are significantly higher than those for traditional generics. Therefore, the transition demands high capital investment and a new talent pool of scientists and researchers who are experts in peptide chemistry, bioprocess engineering, and advanced analytics.

Regulatory standards on peptide drugs continue to tighten globally, particularly around impurity profiling, process control, and data integrity. Indian filers will be measured against EMA and USFDA expectations on this molecule, not against the looser bar of generic-era norms.

Also read: Impact of Global Travel Policies on Medical Tourism in 2026 – What’s in it for Healthcare Businesses? 

What GLP-1 actually proves

GLP-1 is not a generic-manufacturing story dressed up as innovation. It is a test of whether Indian pharma can carry the full complexity stack, from peptide chemistry to deployment infrastructure, that the generics economy was not built for.

The companies that pass that test will earn an export-quality position the country has never held in this segment. The patients who need the drug will benefit only if the deployment side of the system moves at the same speed as the manufacturing side.

India is currently better at the first than the second. Whether that changes is the more interesting question than whether the molecule gets made.

Views expressed by: Saransh Chaudhary, President, Global Critical Care, Venus Remedies Ltd. and CEO, Venus Medicine Research Centre

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

Disclaimer: The views and opinions expressed in this article are solely those of the author and do not necessarily reflect the official policy or views of any organisation. The content is intended for informational and educational purposes only and should not be construed as medical advice.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!